Skip to main content
main-content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Virology Journal 1/2018

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Zeitschrift:
Virology Journal > Ausgabe 1/2018
Autoren:
Aoran Luo, Xiaoyan Jiang, Hong Ren
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12985-018-1050-3) contains supplementary material, which is available to authorized users.

Abstract

Background

Currently, there is no consensus on the efficacy and safety of lamivudine (LAM) plus tenofovir disoproxil fumarate (TDF) combination therapy versus lamivudine monotherapy in HBV/HIV coinfected patients.

Methods

A comprehensive literature search was performed in English and Chinese databases. Both relevant dichotomous and continuous variables were extracted, and the combined outcomes were expressed as a risk ratio (RR) or a standard mean difference (SMD).

Results

Eleven eligible studies were included in our analysis. For HBV-relevant outcomes, the proportion of patients with undetectable HBV, the rates of serum alanine aminotransferase (ALT) normalization and hepatitis B e antigen (HBeAg) loss were higher in the combination therapy group than the monotherapy group (RR = 1.42, 95% CI: 1.14–1.76, P = 0.002; RR = 1.36, 95% CI: 1.17–1.58, P < 0.0001; RR = 2.74, 95% CI: 1.20–6.22, P = 0.02). In addition, the rate of HIV RNA-negative conversion was higher in the combination therapy group than the monotherapy group (RR = 1.26, 95% CI: 1.11–1.42, P = 0.0003).

Conclusion

LAM plus TDF combination therapy was more efficacious than LAM monotherapy in HBV/HIV coinfected patients. As time passes, this difference becomes more pronounced.
Zusatzmaterial
Additional file 1: Figure S1. Subgroup analyses by language. (TIF 7780 kb)
12985_2018_1050_MOESM1_ESM.tif
Additional file 2: Figure S2. Subgroup analyses by study design. (TIF 7777 kb)
12985_2018_1050_MOESM2_ESM.tif
Additional file 3: Figure S3. Subgroup analyses by areas of China. (TIF 7222 kb)
12985_2018_1050_MOESM3_ESM.tif
Additional file 4: Figure S4. Effect of LAM + TDF vs. LAM on HBV DNA levels at the end of treatment. (TIF 3430 kb)
12985_2018_1050_MOESM4_ESM.tif
Additional file 5: Figure S5. Effect of LAM + TDF vs. LAM on the rate of HBeAg loss. (TIF 1169 kb)
12985_2018_1050_MOESM5_ESM.tif
Additional file 6: Figure S6. Galbraith plots of HBV virological response rate(A), levels of HBV DNA(B), subgroups analysis of southern China(C), RCTs(D), 24 weeks(E), and 48 weeks(F). (TIF 6228 kb)
12985_2018_1050_MOESM6_ESM.tif
Additional file 7: Figure S7. Funnel plot for studies included for HBV virological responses. (TIF 516 kb)
12985_2018_1050_MOESM7_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Virology Journal 1/2018 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise